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In both mice and humans, the in vitro culture of normal lymphocytes in
interleukin 2 (IL-2) alone is sufficient to generate cytotoxic cells that lyse an
extensive spectrum of fresh natural killer (NK)-resistant tumor target cells
without MHC restriction, but which do not lyse normal cells (1-3). This has
been termed the lymphokine-activated killer (LAK) phenomenon. Studies from
several laboratories have shown that proliferation of cytotoxic T lymphocytes
and NK cells is also IL-2 dependent (4-6). Recently, the murine lymphokine B
cell stimulatory factor 1 (BSF-1) has been shown to express multiple biologic
activities including B cell, mast cell, and T cell stimulation (7, 8), and interleukin
4 (IL-4) has been proposed as the designation of this factor (8, 9). The cDNA
clones that have been isolated from murine helper T cell lines encode a polypep-
tide of 120 amino acid residues that expresses these activities (8, 9). cDNA clones
have also been obtained for human IL-4 (10). The existence of a polypeptide,
distinct from IL-2, that also possesses a T cell growth factor activity, and the
apparent strict IL-2 dependence ofLAKcellproliferation and function prompted
us to examine the potential LAK-inducing capacity of IL-4. We report here that
murine IL-4 (native and recombinant) stimulation of murine splenocytes can
result in the generation of LAK activity directed against fresh syngeneic tumor
cells. The precursor cell activated by this lymphokine expresses surface asialo-
GM,. Further, we provide evidence that IL-4 can augment the generation of
LAK cytolytic activity induced by IL-2.
Materials and Methods
Mice.
￿
Female C57BL/6 mice, 12-16 wk old, were obtained from TheJackson Labo-
ratory, Bar Harbor, ME, and from the Small Animal Section, Veterinary Resources
Branch, National Cancer Institute.
Tumors.
￿
MCA-102, -105, and -106 are fibrosarcomas induced by intramuscular injec-
tion of0.1 ml of 1% 3-methylcholanthrene (MCA) into the hind limb of C57BL/6 mice
by methods previously described (3). The tumors were maintained by serial passage in
syngeneic hosts and were used in the third to seventh transplant generations. Single-cell
suspensions were prepared from fresh tumors by short trypsinization of small tumor
fragments in 0.25% trypsin in Dulbecco's PBS without calcium or magnesium (from NIH
Media Unit). Released cells were pooled and washed three times to HBSS (Biofluids,
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Rockville, MD) . These tumor cells are resistant to lysis by NK cells and are sensitive to
lysis by LAK cells (11).
Splenocyte Suspensions.
￿
Spleens were removed aseptically and crushed with the hub of
a syringe in complete medium (CM). The cell suspension was passed through 100-gauge
nylon mesh (Nitex; Lawshe Instrument Co., Rockville, MD), and the erythrocytes were
lysed by hypotonic shock with buffered ammonium chloride solution at room temperature
for 2 min. The cells were then centrifuged and washed twice in CM.
CM consisted of RPMI 1640 (Biofluids) with 10% heat-inactivated FCS (Biofluids),
0.03% fresh glutamine (NIH Media Unit), 0.1 mM nonessential amino acids (M. A.
Bioproducts, Walkersville, MD), 5 X 10-5 M 2-ME (Aldrich Chemical Co., Inc., Milwaukee,
WI), 100 Ag/ml penicillin (NIH Media Unit), 100 Eg/ml streptomycin (NIH Media Unit),
50 wg/ml gentamicin (Schering, Kenilworth, NJ), and 0 .5 Ag/ml Fungizone (Flow Labo-
ratories, McLean, VA).
Lymphokines.
￿
Human rIL-2 was kindly supplied by the Cetus Corp., Emeryville, CA.
The biological and biochemical activities of rIL-2 have been described (2). Purified
material had a specific activity of 8 X 106 U/mg as measured in a standard bioassay using
T cell line 53 (2, 3). The endotoxin level in the purified preparation was <0.1 mg per
106 U rIL-2 as measured by a standard limulus assay.
Native interleukin 4 (nIL-4) was purified to homogeneity from the supernatant of the
Con A-induced CI .Ly-1', -2-/9 T cell line (7). rIL-4 was purified to homogeneity from
the supernatant ofCOS-7 monkey cells transfected with a full-length cDNA clone encoding
murine IL-4 (8). The specific activity of both forms was 7 X 107 U/mg in a ['Hlthymidine
HT-2 T cell proliferation assay (7, 8).
Generation of LAK Cells.
￿
1 ml of CM containing 4 X 106 viable C57BL/6 splenocytes
was added to each well of a 24-well Costar tissue culture plate (3524 ; Costar, Cambridge,
MA). 1 ml of CM containing varying amounts of lymphokine was also added to each well.
The cultures were incubated for 4-7 d at 37° C with 5% C02.
Cytotoxicity Assay.
￿
A standard 4-h 5 'Cr-release assay was used to measure cytotoxicity
against tumor cells as described previously (11).
Antibody and Complement Lysis of Splenocytes.
￿
Normal splenocytes were adjusted to a
concentration of 2 X 107 cells/ml of cytotoxicity medium containing a 1 :50 dilution of
rabbit anti-asialo-GM, serum (Wako Chemicals, Dallas, TX). Cytotoxicity medium con-
sisted of RPMI 1640 with 0 .3% BSA and 0.1 mM Hepes buffer. After incubation with
intermittent agitation for 60 min at 4 °C, cells were centrifuged and were resuspended in
a half-equal volume of cytotoxicity medium with rabbit complement (Low-Tox-M; Accu-
rate Chemical and Scientific Corp., Westbury, NY) at 1 :8 dilution. Incubation was
continued for an additional 60 min at 37 ° C with intermittent shaking. The complement
treatment was repeated once again and the cells were then washed twice and were
resuspended in CM.
Results and Discussion
Various concentrations of murine nIL-4, murine rIL-4, human rIL-2, or the
combination of IL-4 plus IL-2 were added to C57BL/6 splenocytes and incubated
for 4 d. These cells were then tested in a 4-h "Cr-release assay for the capacity
to lyse the fresh, syngeneic, NK-resistant sarcoma target, MCA-102 . Table I
shows that 500 U of nIL-4 or 1,000 U of rIL-4/ml generated 141 ± 4 and 461
± 94 LU of LAK activity, respectively. In addition, augmentation of cytolytic
activity with the combination of IL-4 and IL-2 is evident. For example, spleno-
cytes cultured in 500 U/ml of nIL-4 plus rIL-2 for 4 d showed 1,018 f 335 LU,
compared to 180 ± 43 and 141 ± 4 LU when activated with these concentrations
of nIL-4 and rIL-2 alone .
A summary of the data from 15 separate experiments comparing LAK activity
generated by native and recombinant IL-4 alone or in combination with IL-2794
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TABLE I
Generation ofLAK Activity:
Dose Titration of IL-4 and IL-2 vs. Cytolytic Activity
Source of IL-4
Native
Recombinant
C57BL/6 mouse splenocytes were cultured at 2 X 106 cells/ml in 2 ml
of complete medium containing varying amounts of Isymphokine. After
4d the cells were tested for cytolytic activity against 'Cr-labeled, fresh
MCA-inducedsarcoma cells(MCA-102)in a 4-h assay.
* 1 LU is defined as the number of effector cells mediating 30% specific
lysis of 10'target cells, and is determined from the dose-response curve.
LU presented as mean ± SEM of triplicate wells.
against three distinct MCA-sarcoma targets (102, 105, 106) is shown in Table
11. Interexperiment variability in the generation of LAK activity by IL-2 or IL-
4 isevident, since in most experiments suboptimal concentrations oflymphokines
were tested, and we used freshly-resected tumor cells rather than cultured lines
as targets. The recoveries of splenocytes from 4- or 5-d cultures (as a percentage
of the initial number of cells plated) varied slightly between experiments, and
were -50% for IL-2 and 30% for IL-4; those for IL-4 plus IL-2 were equivalent
to IL-2 alone.
We reported previously that the murine precursor cell that gives rise to LAK
cells after HL-2 stimulation expresses surface asialo-GM, (11). Thus we analyzed
whether or not theprecursor activated by IL-4 similarly expressed surface asialo-
GM, by pretreating normal C57BL/6 splenocytes with specific heteroantiserum
plus complement before lymphokine activation. Fig. 1 shows that depletion of
asialo-GM,-positive cells resulted in a near complete elimination ofboth the IL-
IL-4
U/ml
rIL-2 LU* per 10' cells
(mean t SEM)
0 0 <1
0 5 <10
5 0 <1
5 5 <10
0 50 45 ± 11
50 0 <1
50 50 143 ± 12
0 500 180 t 43
500 0 141 ± 4
500 500 1,018 t 335
0 10 63 ± 6
10 0 <1
10 10 102 ± 4
0 100 1,048 ± 110
100 0 <10
100 100 1,045 t 157
0 1,000 648 t 69
1,000 0 461 t 94
1,000 1,000 2,004 t 335E
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TABLE 11
IL-4 Generates LAKActivity andAugments This Activity
in Combination with IL-2
Source of
￿
Tumor target LU per 107 cells(mean ± SEM) with:
* 5-d and 7-d splenocyte cultures were used in experiments 2a, 5, 6, 15, a and b, and
in experiment 26, respectively; 4-d splenocyte cultures were used in all other experi-
ments. Cultures contained 500 U/ml ofeach lymphokine per milliliter of CM, except
for experiment 8, in which theconcentration was 1,000 U, and in experiments 5, 6,
and 15, aand b, in which 200 U rIL-2 and 1,000 U IL-4 were used.
4 and the rIL-2-induced LAK activity. Furthermore, preliminary experiments
(Mule, Smith, and Rosenberg, unpublished results) indicate that specific deple-
tion of mature T cells has little detectable effect on LAK generation by IL-4.
IL-4 generated killer cells do not appear to lyse normal cells. For example, in an
experiment in which IL-4-generated killer cells showed 137 LU ofactivity against
the MCA-102 sarcoma target, <1 LU of activity was noted against syngeneic
fresh peripheral blood lymphocytes, bone marrow, kidney, lung, and LPS-
stimulated splenic blasts.
Taken together, these results demonstrate that the lymphokine IL-4 is capable
of inducing cells with LAKactivity that lyse fresh tumor cell targets in vitro from
anasialo-GM,-positive precursor. IL-4and IL-2 precursor-effector relationships,
as well as the effector phenotype of IL-4-activated killer cells, however, remain
to be determined. Preliminary experiments (Mule et al., unpublished results)
indicate that, unlike IL-2, IL-4 has little ifany capacity to generate LAK activity
from mouse peripheral blood lymphocytes, whereas both lymphokines induce
this activity from splenocytes. Whether or not purified human IL-4 similarly
generates LAK activity from human lymphocytes remains to be'determined.
p.
1
2a
b
3
4a
IL-4
Native
(MCA)
102
102
102
102
102
IL-4
141 ± 4
133 ± 34
81 ± 38
63±6
114±14
IL-2
180 ± 43
305 ± 80
276 ± 84
95±21
90±5
IL-4 + IL-2
1,018 ± 335
1,060± 342
1,469± 315
318±73
105±5
b 105 227 ± 18 79 ± 9 973 ± 140
5a 102 219 ± 27 204 ± 12 1,446± 117
b 105 50 ± 7 58 ± 11 620 ± 109
6a 102 130 ± 13 275 ± 44 277 ± 67
b 105 1,007 ± 284 490 ± 38 1,312 ± 280
7 105 <10 <10 71 ± 9
8 Recombinant 102 461 ±94 648 ± 69 2,004 ± 335
9 102 76 ± 21 143 ± 35 655 ± 298
10a 102 <10 38 ± 6 179 ± 16
6 105 57±8 <10 616±127
11 105 44 ± 11 <10 147 ± 14
12 105 <10 50 ± 20 78 ± 32
13a 102 62 ± 4 148 ± 18 226 ± 29
b 105 66 ± 8 <10 192 ± 73
14 106 42 ± 7 77 ± 27 124± 22
15a 102 171 ± 12 231 ± 33 1,372 ± 77
6 105 340 ± 87 <10 1,778 ± 224796
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FIGURE 1 .
￿
IL-4-activated killer cells arise from asialo-GMI-positive precursors. Splenocytes
were activated in vitro for 4 d in 500 U/ml of lymphokine of CM and were tested in vitro
against fresh MCA-102target cells. Native IL-4 was used in this experiment.Cytolyticactivity
was not detected from splenocyte cultures after elimination of asialo-GMI-positive cells by
heteroantiserum and complement. Symbols and bars represent means and standard errors of
measurements of triplicate wells.
Receivedfor publication 20 May 1987 and in revisedform 15June 1987.
EFFECTOR :TARGET RATIO
IL-4 has been shown to have diverse biologic activities that include: (a)
costimulation with anti-IL antibody to induce proliferation of resting B cells (8,
9), (b) la induction on B cells (12, 13), (c) selective enhancement of IgG1 (14)
and IgE (15) production by mitogen-activated B cells, (d) a mast cell growth
factor activity that synergizes with IL-3, and a T cell growth factor activity (7,
8). The results reported here expand the IL-4 activities to include the induction
of LAK activity from normal resting splenocytes as well as the augmentation of
this activity in combination with IL-2 .
Summary
Interleukin 4 (IL-4) expresses multiple biologic activities, including B cell,
mast cell, and T cell stimulation. We showed that the incubation of resting
splenocytes from C57BL/6 mice solely in purified native or recombinant mouse
IL-4 results in the generation of lymphokine-activated killer (LAK) activity
directed against fresh, syngeneic sarcoma cells. The precursor activated by IL-4
expresses surface asialo-GMI . In addition, IL-4 is capable of amplifying the
splenic LAK activity induced by recombinant IL-2 . The generation, by IL-4, of
killer cells with broad antitumor reactivity raises the possibility of using IL-4
alone or in combination with IL-2 in the immunotherapy of cancer in animal
models.
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